Express News | AH Stocks premium and discount inventory: HOLLY FUTURES, ST Morning Ming, INNOCARE-U premium discount rate increase ranks top.
Hong Kong Stock Midday Review | The three major Indexes all declined, the Hang Seng Index fell by 0.62%; biotechnology and stablecoin Concept stocks rose against the trend, REMEGEN rose nearly 15%, and GUOTAI JUNAN I rose nearly 21%.
Network Technology stocks weakened, Bilibili-W rose by 5.31%, XIAOMI-W fell by 1.20%; Apple Concept stocks generally fell, AAC TECH dropped by 4.48%, SUNNY OPTICAL declined by 2.97%; Biotechnology stocks all rose, REMEGEN increased by 14.93%, AKESO grew by 8.20%.
Hengrui Medicine Gets Drug Registration for Dry Eye Drug
BOCOM INTL reports that in recent months, southbound capital has primarily focused on the Medical and Financial Sectors, indicating an emphasis on the value of high-yield defensive investments.
BOCOM INTL published a report indicating that the Hong Kong stock market performed remarkably in the first half of this year, with the Hang Seng Index and Hang Seng TECH Index recording semi-annual returns of 20% and 18.7% respectively, ranking among the top global major stock indices. Although April's "reciprocal tariffs" temporarily triggered a global stock index pullback, as tariff risks gradually eased, the risk premium falling drove a comprehensive rebound in Hong Kong stocks. By the end of June, the Hang Seng Index was close to its peak for the year, primarily driven by the decline in risk premium, while contributions from risk-free rates and fundamental earnings improvement were relatively limited. Currently, the Hong Kong stocks are in a favorable window period benefiting from multiple bullish factors: the marginal convergence of external disturbances for the market.
Hong Kong stocks fluctuate | Most innovative drug Concepts continue to rise, Huahao Zhongtian Pharmaceuticals rises again by 23%, with a three-day increase of more than double.
On July 4th, GELONGHUY reported that most Hong Kong stocks in the innovative pharmaceutical Concept continued to strengthen, with Huazhao Zhongtian Pharmaceutical leading the way with a rise of 23.55%, and having increased over 120% in the past three days. AKESO rose by 5.66%, with Yunding Xinyao, Hengrui Pharmaceuticals, WUXI XDC, SINO BIOPHARM, WUXI APPTEC, and FOSUN PHARMA also rising. In news, on July 1st, the National Medical Insurance Administration and the National Health and Family Planning Commission jointly issued "Several Measures to Support the High-Quality Development of Innovative Drugs" focusing on the prominent issues facing the development of innovative drugs in China, proposing 16 measures in 5 areas, aimed at building a full-chain support system for innovation from research and development, market access, payment to clinical application.
Hengrui Pharmaceuticals (600276): The time for the international transformation has come, bullish on the company's pipeline's global competitiveness.
Introduction to this report: Hengrui Pharmaceuticals has undergone 15 years of international transformation, accumulating rich international experience. By reviewing the company's international transformation process and deeply analyzing the company's research pipeline, it is believed that the company has entered the period of realizing its transformation. On one hand,
Hong Kong Stock Announcement Gold Mining | Alibaba plans to issue approximately 12 billion HKD zero-coupon convertible Bonds. Anjoy Foods Group will be listed tomorrow.
Hengrui Pharmaceuticals (01276): SHR-4506 injection has obtained approval for clinical trials, and perfluorohexyl octanoate eye drops have been approved for marketing.
Hengrui Pharmaceuticals: SHR-4506 injection has received the drug clinical trial approval notification.
On July 3, Gelonghui reported that Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Suzhou Shengdiya CNI Biomedicine received the approval for the clinical trial notification concerning SHR-4506 injection from the National Medical Products Administration and will soon begin clinical trials. SHR-4506 injection is a class I therapeutic biologics independently developed by the company, which has demonstrated good anti-tumor activity in preclinical animal models and aims to be used for the treatment of advanced malignant tumors.
Hengrui Pharmaceuticals: Perfluorohexyl octanol eye drops have received drug registration approval.
Gelonghui, July 3rd丨Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. received a notice from the National Medical Products Administration, approving the launch of the product perfluorohexyl octane eye drops, used for the treatment of dry eye associated with meibomian gland dysfunction (MGD).
H Share Announcement-Monthly Statement of Securities Changes
Hong Kong stock movement | Hengrui Pharmaceuticals rose about 5%, gaining 0.3625 million shares in shareholding from Wellington. Morgan Stanley initiated coverage with an "outperform" rating.
Gelonghui, July 2 | Hengrui Pharmaceuticals (1276.HK) rose by 4.93% to HKD 56.45 during intraday trading today. The latest equity disclosure data from the Stock Exchange shows that on June 26, Hengrui Pharmaceuticals had Wellington Management Group LLP increase its shareholding by 0.3625 million shares at an average price of HKD 56.0764 per share, involving approximately HKD 20.3255 million. After the increase, its shareholding ratio rose from 4.94% to 5.08%. Morgan Stanley's Research Reports indicated that Hengrui Pharmaceuticals has the most extensive and balanced product portfolio and pipeline among domestic pharmaceutical companies.
Express News | Morgan Stanley: Assigning a Shareholding rating to Hengrui Pharmaceuticals with a Target Price of 78 Hong Kong dollars.
Morgan Stanley has initiated coverage on Hengrui Pharmaceuticals (01276.HK) with a "Shareholding" rating and a Target Price of 78 yuan.
Morgan Stanley published a research report, stating that Hengrui Pharmaceuticals (01276.HK) has the most extensive and balanced product portfolio and pipeline among domestic pharmaceutical companies, expecting 47 new drugs to be approved and launched from 2025 to 2027. Since 2018, the company has had 14 external licensing Trades, involving a total of 15 billion USD, covering different phases and technology platforms. With increasing interest from international pharmaceutical companies in acquiring Assets of domestic pharmaceutical firms, the bank anticipates more external licensing Trades in the future. The bank estimates that Hengrui's annual compound growth rate for innovative drug sales will be 34% from 2024 to 2027, with the company's revenue and net profit.
The Concept of innovative drugs in Hong Kong stocks has surged and then retreated, with funds quietly entering the market in two ways.
① What changes will the supportive policies for innovative drugs bring? ② Through what channels has funding increased the positions of innovative drug-related varieties?
The Hong Kong stock market's innovative drug Concept is performing strongly, with two departments issuing 16 measures to support innovative drugs, accelerating the momentum for pharmaceutical innovation.
On the news front, on July 1, the National Healthcare Security Administration and the National Health Commission jointly issued "Several Measures to Support the High-Quality Development of Innovative Drugs" which focuses on the prominent issues facing the development of innovative drugs in China. It proposes 16 measures in 5 areas, aiming to build a comprehensive support system for the development of innovative drugs from research and development, market access, payment to clinical application.
The Hong Kong stock market's innovative drug Sector has risen, with policy support for Industry development, and Institutions claim that the momentum for medical innovation is accelerating.
The era of true innovation and true internationalization in medicine will soon bring rewards.
The directory of innovative drugs for commercial insurance has been officially included! The national negotiation plan for 2025 has begun to seek opinions, and the "dual export" of innovative drugs is being launched simultaneously.
① The directory of commercial innovative drugs is expected to be officially introduced for national discussion. ② Eligible exclusive drugs can be declared separately for the commercial insurance innovative drug directory or simultaneously for both the commercial insurance innovative drug directory and the basic directory. ③ Some enterprises have informed the Financial Association reporter that they will actively participate in the declaration of the commercial insurance innovative drug directory.
Hong Kong stock Concept tracking | Important document released! A-shares of innovative drugs surged by 3% in response. Institutions claim that the re-evaluation of innovative drug Assets will continue (attached Concept stocks).
On July 1st, the A-share Hithink RoyalFlush Information Network innovative drug Sector rose by 3%, with a cumulative increase of 25% this year, and related Concept stocks continued to rise in the afternoon.
Hengrui Pharmaceutical Gets China Nod for New Indication of Drug for Alopecia Areata
The ranking of Chinese enterprises' IPOs for the first half of 2025 has been released, with fundraising amounting to nearly 140 billion yuan.
In the first half of 2025, the number of Chinese enterprises listed slightly decreased compared to the second half of last year, but the amount of funds raised approached 140 billion yuan, showing significant growth. It is worth noting that the Hong Kong stock market has become a key financing channel for Chinese enterprise IPOs.